ASSAIL-MI (ASSessing the Effect ofAnti-IL-6 Treatment in Myocardial Infarction) was a randomizedplacebo-controlled study included 199 patients with the first ST-elevationmyocardial infarction (STEMI) presenting within 6 hours of symptom onset [42].Prior to percutaneous coronary intervention (PCI), patients were randomized toreceive tocilizumab (in a dose of 280 mg as a single infusion), or placebo. The gene discussed is IL6; the disease is myocardial infarction.